While it is clear that combination approaches that look at simultaneous or sequential use of immunotherapeutic approaches with agents that target the RAF/MEK/ERK pathway are also a priority, it is not time to divert attention away from the pathway that induces such profound oncogene addiction in melanoma patients whose tumors contain activating mutations in BRAF. This evidence concerns the gene RAF1 and melanoma.